HomeCONGRESS

CONGRESS

View Category
Day 1

TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes

Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present...
solaci -
Learn More
Day 1

TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days

The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain....
solaci -
Learn More
Day 1

RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.

The use of vitamin K antagonists provides excellent protection against thromboembolic complications in patients with mechanical valves,...
solaci -
Learn More
Day 1

Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .

The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke ....
solaci -
Learn More
Day 1

ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.

This study evaluated the administration of prasugrel at the time of diagnosis of non-ST segment acute coronary...
solaci -
Learn More
Day 3

ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure

This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on...
solaci -
Learn More
Day 2

PURE: Cardiovascular disease contrast between developed and undeveloped countries.

80% of the global burden of cardiovascular disease is located in countries with low or middle incomes....
solaci -
Learn More
Day 3

Resynchronization therapy is not beneficial in patients with heart failure and narrow QRS

Resynchronization therapy has shown benefits reducing morbidity and mortality in patients with heart failure and wide QRS....
solaci -
Learn More